News Center


From the screening of cell lines to cell culture development, Henlius professional team make effort in maximizing output, while ensuring high quality of products. Our international standard laboratory is equipped with advanced equipment, and we make use of our abundant technical and scientific expertise to develop and optimize the production process...

2018 Company Memorabilia

  • 01
  • 02
  • 03
  • 04
  • 05
  • 06
  • 07
  • 08
  • 09
  • 10
  • 11
  • 12
  • 13
HLX01 was under priority review for marketing authorisation by the NMPA
Scientific Advisory Board was established with four world-renowned scientists and experts joining in the Company
We entered Phase 3 clinical trial for HLX01 with respect to RA
The Company entered into licence and commercialisation agreements with multiple partners, including Accord from UK, Cipla, a top international pharmaceutical company and Biosidus, a biopharmaceutical pioneer from Argentina, to enter into additional strategic collaboration agreements with international partners.
The Company subscribed from 9 investors for an aggregate of US$156.5 million at a subscription price of US$6.23 per Share, making the Post-Money Valuation hit US$2.9565 billion
The Company received IND approval to develop HLX20 in Australia and China and commenced a Phase 1 clinical trial in Australia.
HLX07 commenced a Phase 1b/2 clinical trial in Mainland China
HLX01 Phase 3 Clinical Trial with respect to NHL was done and the clinical trial data of Phase 1b and 3 were released in the 21th CSCO Annual Conference.
The Company received IND approval for HLX12 for late-stage Gastric Cancer or Adenocarcinoma of Esophagogastric junction, metastatic Non-Small Cell Lung Cancer and metastatic colorectal cancer.
The Company entered into an exclusive licence agreement with AbClon from Korea to globally develop and commercialise its proprietary antibody AC101.
The Company filed public offering application to the Stock Exchange of Hong Kong Ltd. via Joint Sponsor
Two projects got initiated and sponsored by the national major new medicine project in the 13th Five-year Plan
The Company developed the first mAb combination therapy in China and received approval. It has completed the first subject enrollment.


In Henlius, employees are of overriding importance and talents are the most valuable assets for the company. We recognize talents and make the best of them through cultivation with professional trainings to retain them......

Recruiting Position